Vaccine Innovation. Beyond Convention.
We are dedicated to eliminating bacterial infections such as invasive pneumococcal disease, Group A Strep, periodontitis and Shigella to protect every child born and every adult at risk across the globe.
Pushing the Boundaries of What’s Possible
Despite widespread vaccination with current pneumococcal conjugate vaccines (PCVs), there is an abundance of non-vaccine strains of the Streptococcus pneumoniae bacteria causing significant morbidity and mortality. This underscores the importance of advancing VAX-24, our lead 24-valent PCV candidate, which is the broadest-spectrum PCV in the clinic today. Upon achieving clinical proof-of-concept, VAX-24 was granted FDA Breakthrough Therapy designation for the prevention of invasive pneumococcal disease in adults.
Re-Engineering How Vaccines are Made
We strive to overcome the limitations of conventional, cell-based vaccine approaches using advanced chemistry and modern synthetic techniques – including our XpressCF™ cell-free protein synthesis platform – to produce broad-spectrum vaccines that are uniquely capable of breaking down bacteria’s complex defense mechanisms while preserving immunogenicity.
Building a Pipeline of High-Fidelity and Broad-Spectrum Vaccines
Our PCV franchise is intended to improve upon existing pneumococcal vaccines by covering a significant portion of the invasive pneumococcal disease currently in circulation that is associated with high case-fatality rates, antibiotic resistance and meningitis. Following VAX-24, we are developing VAX-31, a 31-valent PCV candidate. Additional vaccine candidates in preclinical development target Group A Strep, periodontitis and Shigella.
Latest News
Vaxcyte to Present at the Jefferies Healthcare Conference
Vaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update
Vaxcyte to Present at the BofA Securities 2023 Health Care Conference
Careers: Built to Scale with Purpose
Looking for higher aspirations to ignite your mind and inspire your heart? Then join a team that brings grit and grace to the challenge of protecting every human from the consequences of endemic bacterial infections.